NCT06018428Phase 2Active, not recruiting
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
In the register
The register attaches this trial to Bempikibart (ADX-914) (Q32 Bio), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 2
- Sponsor
- Q32 Bio Inc.
- Participants (registry)
- 75
- Start
- September 2023
- Primary completion
- June 2026
- Study completion
- September 2026
- Last registry update
- May 2026
- Countries
- United States, Canada
Conditions studied: Alopecia Areata
Interventions: bempikibart (ADX-914)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.